OTCM
COTXF
Market cap2mUSD
Sep 08, Last price
0.12USD
1Q
-7.64%
IPO
3.33%
Name
Roquefort Therapeutics PLC
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0
-100.00%
Net income
-972k
L-44.29%
CFO
-784k
L-54.79%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Roquefort Therapeutics plc functions as a biotechnology firm, focusing its efforts on the discovery and development of innovative pharmaceutical treatments. The company's primary research objective is to develop therapies that target Midkine, a circulating growth factor protein and pro-inflammatory mediator, for applications in cancer treatment. Established in 2020, Roquefort Therapeutics plc has its main operations based in London, United Kingdom.
Headquarters & legal address
85 Great Portland Street
First Floor
London W1W 7LT
GB
First Floor
London W1W 7LT
GB
Previous name
Roquefort Investments PLC
Previous name
Roquefort Therapeutics PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | ||||
Revenues | ||||
Cost of revenue | ||||
Unusual Expense (Income) | ||||
NOPBT | ||||
NOPBT Margin | ||||
Operating Taxes | ||||
Tax Rate | ||||
NOPAT | ||||
Net income | ||||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | ||||
BB yield | ||||
| Debt | ||||
Debt current | ||||
Long-term debt | ||||
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | ||||
| Cash flow | ||||
Cash from operating activities | ||||
CAPEX | ||||
Cash from investing activities | ||||
Cash from financing activities | ||||
FCF | ||||
| Balance | ||||
Cash | ||||
Long term investments | ||||
Excess cash | ||||
Stockholders' equity | ||||
Invested Capital | ||||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | ||||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | ||||
EV/EBITDA | ||||
Interest | ||||
Interest/NOPBT | ||||